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Abstract
Purpose Although therapeutic dosages of most low-
molecular-weight heparins (LMWHs) are known to accumu-
late in patients with renal insufficiency, for the lower prophy-
lactic dosages this has not been clearly proven. Nevertheless,
dose reduction is often recommended. We conducted a sys-
tematic review to investigate whether prophylactic dosages of
LMWH accumulate in renal insufficient patients.
Methods A comprehensive search was conducted on 17 Feb-
ruary 2015 using Embase, Medline, Web of Science, Scopus,
Cochrane, PubMed publisher, and Google scholar. The syntax
emphasized for LMWHs, impaired renal function, and phar-
macokinetics. The search yielded 674 publications. After ex-
clusion by reading the titles, abstracts, and if necessary the full
paper, 11 publications remained.
Results For dalteparin and tinzaparin, no accumulation was
observed. Enoxaparin, on the other hand, did lead to accumu-
lation in patients with renal insufficiency, although not in pa-
tients undergoing renal replacement therapy. Bemiparin and
certoparin also did show accumulation. No data were avail-
able for nadroparin.
Conclusions In this systematic review, we show that prophy-
lactic dosages of tinzaparin and dalteparin are likely to be safe
in patients with renal insufficiency and do not need dose re-
duction based on the absence of accumulation. However, pro-
phylactic dosages of enoxaparin, bemiparin, and certoparin
did show accumulation in patients with a creatinine clearance
(CrCl) below 30 ml/min, and therefore, dose reduction is re-
quired. The differences in occurrence of accumulation seem to
depend on the mean molecular weight of LMWHs.
Keywords Clinical trials . Heparins . Pharmacodynamics .
Heparins . Venous thrombosis
Introduction
Low-molecular-weight heparins (LMWHs) are anticoagulants
made by depolymerization of unfractioned heparin (UFH) [1,
2]. In the last decades, LMWHs have largely replaced UFH as
anticoagulants, because they are at least equally effective in
prevention and treatment of venous thromboembolisms
(VTEs) and have many practical advantages, most important-
ly the possibility of subcutaneous administration without the
need of routine laboratory monitoring of the anticoagulant
response [3–8]. Moreover, LMWHs have a more predictable
anticoagulant response, longer half-life (allowing once or
twice daily administration), and a dose-independent elimina-
tion and they cause less heparin-induced thrombocytopenia
[1, 2, 9, 10]. There is conflicting evidence whether bleeding
complications differ between LMWHs and UFH, although a
Cochrane analysis showed that LMWHs reduce the occur-
rence of major bleedings [8, 11–14].
The molecular weights of the various LMWHs differ.
Tinzaparin has the highest average molecular weight
(6500 Da), while certoparin has the lowest average molecular
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weight (3800 Da) [13]. Pharmacokinetics of different
LMWHs vary: they differ in elimination half-life, clearance,
and bioavailability [15, 16]. This might be a consequence of
the differences in molecular weight. Also with regard to phar-
macodynamics, LMWHs vary: anti-Xa/anti-IIa activity ratios
range between 1.5 and 2.5 (tinzaparin and certoparin) to 3.6–
6.5 (reviparin) [13].
Since LMWHs are mainly excreted by the kidney, they
may accumulate in patients with renal insufficiency increasing
the risk of bleeding [17–19]. Due to above-described differ-
ences in pharmacokinetics, data on accumulation in renal in-
sufficiency cannot be easily converted from one LMWH to
another [2]. For instance, therapeutic dosages of different
LMWHs do not all accumulate in patients with renal insuffi-
ciency: nadroparin and enoxaparin were found to accumulate,
while tinzaparin did not [20–26]. For LMHWs that accumu-
late in a therapeutic dosage, dose reduction is often recom-
mended. Also for the lower prophylactic dosages, such dose
reductions have been suggested, especially for high prophy-
lactic dosages such as those used in cancer patients or in high-
risk surgery [24, 27–29].
Even in this era of novel oral anticoagulants, LMWHs will
stay important for the initial treatment of VTE during the first
5–7 days in patients treated with dabigatran and edoxaban, as
well as for prophylaxis of VTE. Especially for patients with
severe renal insufficiency in which case the novel oral antico-
agulants are contraindicated, it remains important to know
whether LMWHs can be prescribed safely.
Therefore, we conducted a systematic review to investigate
whether prophylactic dosages of various LMWHs lead to ac-
cumulation defined as an increase in anti-Xa activity and
whether accumulation depends on molecular weight of the
LMWH.
Materials and methods
The meta-analysis was prepared in accordance with the PRIS
MA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement [30]. No prespecified formal proto-
col was registered.
Article search
A comprehensive, systematic literature search has been con-
ducted on 17 February 2015 using Embase, Medline, Web of
Science, Scopus, Cochrane, PubMed publisher, and Google
scholar. The syntax emphasized for LMWHs, impaired renal
function, and pharmacokinetics using synonyms and relevant
terms. The search terms as used in Embase, as an example, are
shown in a supplemental file. In addition to the search results,
we manually searched reference lists of all relevant articles for
additional studies.
Inclusion criteria and exclusion criteria (eligibility
criteria)
We only included articles in English on prophylactic LMWH
treatment, studying at least ten patients (non-pregnant and
with no children) with renal impairment. We defined accumu-
lation as an increase in anti-Xa activity after consecutive ad-
ministration for several days. Therefore, we excluded studies
which did not administer LMWH on consecutive days (except
for studies in patients receiving renal replacement therapy)
and did not measure anti-Xa activity on multiple days while
giving LMWH. We excluded case reports, overviews, expert
opinions, recommendations, reviews, and replies on articles.
Abstracts of unpublished data were not excluded; authors
were approached for additional information.
Study selection and data collection
A single reviewer excluded articles that did not meet the eli-
gibility criteria by using the title and abstract. If necessary, the
full text was read. If the reviewer could not decide whether to
exclude the article, a second reviewer was asked for advice
and both met to reach a consensus. Furthermore, a single
reviewer collected relevant data from the included articles
for the review.
Risk of bias
Risk of bias was evaluated at study level using the Cochrane
Risk of Bias assessment tool. The criteria on random sequence
generation, allocation, and blinding were disregarded.
Results
Study selection
The search yielded 1387 articles from which 713 were dupli-
cates. Figure 1 shows a flow diagram illustrating literature
evaluation.
Characteristics
Table 1 shows the study and patient characteristics.We includ-
ed 11 articles of which one was on LMWH in continuous
venovenous hemofiltration (CVVH) and one on hemodialysis
patients. Five studies examined dalteparin accumulation, and
five articles examined enoxaparin [31–37, 40, 41]. For
tinzaparin, bemiparin, and certoparin, there was one study
for each LMWH [35, 38, 39].
All studies were conducted prospectively. Two were ran-
domized trials, and eight were cohort studies. Only one study
did report clear prespecified primary outcomes. The number of
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patients ranged between 12 and 138. Three studies only includ-
ed patients on an intensive care unit (ICU), and three studies
only included elderly patients (Table 1). The follow-up length
per patient was 4 days to 3 weeks. Accumulation was mainly
assessed by measuring peak anti-Xa activity or trough anti-Xa
activity (Table 2). Six studies reported clinical outcomes like
hemorrhagic events, thrombosis, and mortality rates.
Dalteparin
Dalteparin accumulation was studied in five articles. In pa-
tients on a general medical or surgical ward, no accumulation
was found in a total of 157 patients bymeasuring peak anti-Xa
activity on day 6 or day 10 [32, 34].
At the ICU, trough and peak anti-Xa activity did not show
accumulation on day 9 or day 12 in a total of 157 patients not
undergoing CVVH [31, 33].
Also in hemodialysis patients (n=7) prescribed 2500 IU
dalteparin during hemodialysis sessions for 4 weeks, anti-Xa
activity at different time points (1, 2, 3, 4, 24, and 28 h post-
injection) were not significantly different between week 1 and
week 4 [40]. The patients underwent hemodialysis sessions
three times a week for 4 h.
Enoxaparin
Three studies of which two in patients older than 75 years
examined enoxaparin accumulation in, respectively, 125, 28,
and 48 non-dialysis patients [35–37]. The studies in the elder-
ly with CrCl 20–50 ml/min found a significantly higher max-
imum concentration (Cmax), area under the curve (AUC), and
trough anti-Xa activity (24 h postinjection) after 8 days
administration and a higher peak anti-Xa activity after 10 days,
compared to patients with better renal function [35, 36]. The
other study in patients with different severity of renal insuffi-
ciency found accumulation (a significantly higher Cmax, lon-
ger half-life, higher AUC) already on day 4 in patients with
CrCl≤30 ml/min [37].
Hemodialysis patients (n=7) prescribed 40 mg enoxaparin
at hemodialysis sessions for 4 weeks, anti-Xa activity at dif-
ferent time points postinjectionwere not significantly different
betweenweek 1 and week 4 [40]. Also in ICU patients (n=12)
undergoing CVVH with a flow rate of 30 ml/kg/h, no accu-
mulation of enoxaparin (30 mg daily) was found [41].
Tinzaparin, bemiparin, and certoparin
Administration of 4500 IU tinzaparin for 8 days in 27 patients
older than 75 years with CrCl 20–50 ml/min and body weight
below 65 kg did not lead to significant changes inCmax, AUC,
and trough anti-Xa activity (24 h postinjection) [35].
For 3500 IU bemiparin,Cmax was higher andmean half-life
was 2–4 h prolonged in patients with severe renal insufficien-
cy after 4 days administration in 48 patients [38]. AUC sig-
nificantly increased with the degree of renal insufficiency.
For 3000 IU certoparin, Cmax and AUC were significantly
higher in patients with renal insufficiency compared to healthy
controls after 5 days administration in 24 patients [39].
Adverse events
Six studies reported VTEs and bleeding events, although
all were underpowered to find significant correlations
[31–36]. In three of these studies, anti-Xa activity was
Fig. 1 Flow diagram illustrating literature evaluation
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undetectable during bleeding [31, 33, 34]. Five serious
bleeding complications were reported when using
enoxaparin, but anti-Xa activity in these patients was
the same as in those without bleeding (p=0.77) [36].
Table 2 Outcomes of included studies
LMWH Parameter Results
Dalteparin 5000 IU [31] Trough anti-Xa Three patients value(s)>detection threshold; none above accumulation threshold
Peak anti-Xa Mean 0.30 U/ml (95 % CI 0.27–0.33)
Day 1 Day 10
Dalteparin 2500, 5000,
and 7500 IU [32]
CrCl>60 CrCl 30–59 CrCl<30 CrCl>60 CrCl 30–59 CrCl<30
Peak anti-Xa
(range)
0.28b
(0.20–0.32)
0.31b
(0.23–0.46)
0.28b
(0.23–0.33)
0.27a,b
(0.16–0.35)
0.48a,b
(0.31–0.51)
0.39a,b
(0.31–0.50)
Dalteparin 5000 IU [33] Trough anti-Xa Seven patients value(s)>detection threshold; none above accumulation threshold
Day 3 Day 10 Day 17
Peak anti-Xa
(range)
0.29 (0.20–0.42)a 0.35 (0.24–0.43)a 0.34 (0.27–0.45)a
Dalteparin 2500 and
5000 IU [34]
Day 6
CrCl>60 CrCl 30–59 CrCl<30
Peak anti-Xa
(range)
0.030 (0.086)b 0.033 (0.075)b 0.048 (0.084)b
Day 1 Day 8 p value
Enoxaparin 4000 IU
Tinzaparin 4500 IU [35]
Enoxaparin Tinzaparin Enoxaparin Tinzaparin Enoxaparin Tinzaparin
Cmax 0.55 (0.14) 0.44 (0.16) 0.67 (0.23) 0.46 (0.19) <0.001 0.296
AUC 354 (119) 252 (103) 447 (218) 273 (111) <0.001 0.11
Trough 0.06 (0.06) 0.05 (0.04) 0.11 (0.10) 0.06 (0.06) 0.013 0.17
Enoxaparin 4000 IU [36] CrCl 51–80 CrCl 41–50 CrCl 31–40 CrCl 20–30
Anti-Xamax 1–10 0.60 (0.16) 0.61 (0.17) 0.61 (0.24) 0.72 (0.27)
p value 0.030c 0.039c 0.039c Ref
Enoxaparin 4000 IU [37] Severe RI
Cmax 10–35 % higher
AUC(0–24) 65 % higher (day 4)
CL/F 27 % (day 1), 39 % (day 4)
t1/2λz Increased with the degree of RI (p<0.012)
Bemiparin 3500 IU [38] Severe RI
Cmax Higher
t1/2 2–4 h prolonged
CL/F Lower
AUC Increased with the degree of RI
Certoparin 3000 IU [39] Severe RI Ratio severe RI/normal renal function
Cmax day 5 0.27 (range 0.16–0.70) 1.39 (95 % CI 1.04–1.85)
AUC(0–24) 2.28 (range 1.35–5.11) 1.52 (95 % CI 1.07–2.17)
Enoxaparin 4000 IU,
Dalteparin 2500 IU [40]
Week 1a Week 4a
Dalteparin Enoxaparin Dalteparin Enoxaparin
Anti-Xa (SEM) 0.2 (0.035) 0.38 (0.028) 0.26 (0.038) 0.40 (0.055)
Enoxaparin 3000 IU [41] Trough anti-Xa Mean 0.11 (range 0.01–0.27, SD 0.07). None above accumulation threshold.
All studies administered a once daily dosage. Peak anti-Xa: activity 4 h postinjection in all studies (all anti-Xa activity in IU/ml
IQR interquartile range, CrCl creatinine clearance in ml/min, Cmaxmaximum concentration, AUC area under the curve, Anti-Xamax 1–10 maximum anti-
Xa activity in 10 days, AUC(0–24) area under the 24 h plasma activity time curve, CL/F apparent total body clearance, RI renal insufficiency, t1/2
elimination half-life, t1/2λz apparent terminal elimination half-life, SEM standard error of the mean
aNo significant changes between day 1 and day x
b No significant changes between groups on day x
c Compared to CrCl 20–30 ml/min
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Discussion
In this systematic review, we show that prophylactic
dosages of dalteparin and tinzaparin did not accumulate
in patients with renal insufficiency, while prophylactic
dosages of enoxaparin, bemiparin, and certoparin did
accumulate. Dalteparin also showed no accumulation in
hemodialysis patients. Surprisingly, enoxaparin did not
show accumulation in hemodialysis and CVVH patients,
which might be due to removal by renal replacement
therapy [42]. No data are available for nadroparin in
patients with renal insufficiency.
These results are in accordance with studies on therapeutic
dosages, except for dalteparin. Dalteparin is the only LMWH
that appears to accumulate when used in a therapeutic dosage,
while in studies using prophylactic dosages no accumulation
was detected [31–34, 43]. A single-dose study showed re-
duced elimination of prophylactic dalteparin in patients with
renal insufficiency, but apparently clearance is sufficient to
prevent accumulation [31–34, 44].
Data on assessment of accumulation on prophylactic
nadroparin in renal insufficiency are lacking. Only one
multiple-dose study in six patients with CrCl above 30 ml/
min and one single-dose study were conducted [45, 46].
Our findings confirm the theory that accumulation seems to
depend on the mean molecular weight of LMWHs as shown
in Table 3. LMWHs with the lowest molecular weight
(enoxaparin, bemiparin, certoparin, and nadroparin) all
showed accumulation in a therapeutic dosage and a prophy-
lactic dosage. Tinzaparin (the LMWH with the highest mean
molecular weight) has shown not to accumulate in neither
therapeutic nor prophylactic dosage. The most likely explana-
tion for this counterintuitive relationship between size and
accumulation is that the larger molecules are less dependent
on renal clearance [4, 28, 49, 50].
In patients undergoing renal replacement therapy, it has
been shown that many LMWHs are safe to use even in ther-
apeutic dosages [28, 51]. For assessment of accumulation,
only a few studies have been conducted. Most of these studies
were excluded from this review as they included a single bolus
administration, a therapeutic dosage, or no anti-Xa activity
measuring at multiple days. Dalteparin showed accumulation
in hemodialysis patients if prescribed in a therapeutic dosage,
but not in a prophylactic dosage, whereas accumulation was
found for prophylactic dosage in peritoneal dialysis patients
[19, 40, 52]. Prophylactic dosages of enoxaparin and prophy-
lactic and therapeutic dosages of nadroparin showed no accu-
mulation in hemodialysis and CVVH patients [40, 41, 53, 54].
Tinzaparin accumulation has been found in a therapeutic dose
in hemodialysis patients, but in a prophylactic dose, anti-Xa
activity returned to baseline in 24 h [52, 55]. In conclusion, for
dalteparin accumulation in renal replacement therapy is com-
parable to accumulation in patients without renal replacement
therapy, but in other LMWHs accumulation in renal replace-
ment therapy seems not to depend on mean molecular weight
of LMWHs. The mechanism for accumulation in renal re-
placement therapy is unknown, but the highly negative charge
of LMWHs might play a role [52]. More studies are needed to
assess LMWH accumulation in patients on renal replacement
therapy.
The strength of this review is first that we included only
articles that objectively observed accumulation based on anti-
Xa activity rather than an accumulation prediction based on
the half-life or the time it takes for anti-Xa activity to return to
baseline. Second, by including the recent studies on bemiparin
and certoparin, this paper confirms the earlier stated theory
Table 3 Accumulation
dependency on molecular weight LMWH Mean molecular
weight (Da) [13, 47]
Accumulation therapeutic Accumulation prophylactic
Bemiparin 3600 CrCl<30 ml/min [38] CrCl<30 ml/min [38]
Certoparin 3800 CrCl<30 ml/min [48] CrCl<30 ml/min [39]
Nadroparin 4300 Yesa [20] No conclusionb
Enoxaparin 4500 CrCl<30 ml/min [21–24] CrCl<30 ml/min 4 days [37]
and 20–50 ml/min 8 days [35]
Dalteparin 6000 CrCl<30 ml/min after 6 days [32],
but not after 3 [43]
Noc [31–34]
Tinzaparin 6500 Nod [25, 26] Nod [35]
CrCl creatinine clearance
a Only correlation GFR/anti-Xa activity reported, no specific accumulation limit
b Only one multiple dose study in six patients with CrCl above 30 ml/min and one single intravenous dose study
[45, 46]
c Largest study no lower limit for CrCl33
d CrCl>20 ml/min
926 Eur J Clin Pharmacol (2015) 71:921–929
that accumulation depends on the mean molecular weight of
LMWHs.
A limitation might be that we did not include single-
dose studies. However, a single-dose study is not suitable
for objectively detecting accumulation [28, 32]. A signifi-
cantly lower clearance or prolonged half-life for a LMWH
in a single-dose study does not necessarily indicate that
the LMWH accumulates, as is clear from the findings on
dalteparin. Furthermore, follow-up of patients in some
studies was relatively short (in some studies less than
1 week); however, if LMWHs would accumulate, this
would be noticeable already after three dosages. Given
the fact that patients tend to be discharged from the hos-
pital within a few days, it is hardly possible to perform
clinical studies with longer follow-up.
Another limitation might be that the risk of bias could not
be assessed accurately. Considering bias across studies, we
feel that a publication bias seems unlikely since both negative
and positive outcomes in studies on accumulation have news
value, and we included two abstracts of unpublished data.
Furthermore, a possible confounder could be the difference
in renal insufficiency onset (acute vs chronic) in different
studies; however, there is no evidence that this can cause var-
iance in anti-Xa activity.
A major limitation of all studies is that anti-Xa activity
rather than hard clinical endpoints were studied. Although a
study on hard clinical endpoints in patients with renal insuffi-
ciency is probably not feasible due to large numbers needed, it
should be taken into account that the correlation between anti-
Xa activity and occurrence of bleeding or VTE is not unam-
biguous [56–60]. The therapeutic and prophylactic target
levels of anti-Xa activity are not supported by evidence of
trials, but they are rather based on expert opinions [61, 62].
We also found in our review that in six studies that reported
clinical outcomes, none of the patients with bleeding had
higher anti-Xa activity than patients without bleeding
[31–36]. However, the anti-Xa activity is considered to be
the best test available tomeasure LMWHactivity and to detect
accumulation of LMWHs [4, 63].
In conclusion, for several LMWHs the guidelines that rec-
ommend dose reduction for prophylactic use in patients with
renal insufficiency are evidence based, except for dalteparin,
tinzaparin, and nadroparin. We recommend a dose reduction
for prophylactic use of enoxaparin, bemiparin, and certoparin
in patients with CrCl below 30 ml/min [24, 28, 29, 38, 39].
Prophylactic dosages of tinzaparin and dalteparin are likely to
be safe in patients with renal insufficiency and do not need
dose reduction. Studies are needed to assess accumulation of
prophylactic dosages of nadroparin and for all LMWHs in
patients undergoing renal replacement therapy.
Acknowledgments This work was funded by the Dutch Kidney Foun-
dation (Safety of medication in renal insufficiency, MV 13.36)
Authors’ Contributions F. Atiq contributed to the conception and de-
sign of the work, data acquisition and analysis, and writing of the manu-
script. P.M.L.A. van den Bemt and F.W.G. Leebeek contributed to the
conception and design of the work and revised the manuscript critically.
T. van Gelder contributed to the conception and design of the work and
data analysis and revised the manuscript critically. J. Versmissen contrib-
uted to the conception and design of the work, data acquisition and anal-
ysis, and writing and revising of the manuscript. All authors approved the
final version of the manuscript.
Conflict of interest The authors declare that they have no competing
interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood
79(1):1–17
2. Hetzel GR, Sucker C (2005) The heparins: all a nephrologist should
know. Nephrol Dial Transplant 20(10):2036–2042
3. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med
337(10):688–698
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL,
Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and
low-molecular-weight heparin: mechanisms of action, pharmacoki-
netics, dosing, monitoring, efficacy, and safety. Chest 119(1
SUPPL):64S–94S
5. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH
(2001) Deep vein thrombosis and its prevention in critically ill
adults. Arch Intern Med 161(10):1268–1279
6. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes
DW, Vandenbroucke JP, Briet E (1992) Low-molecular-weight
heparin versus standard heparin in general and orthopaedic surgery:
a meta-analysis. Lancet 340(8812):152–156
7. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM
(1999) Low-molecular-weight heparins compared with
unfractionated heparin for treatment of acute deep venous throm-
bosis. A meta-analysis of randomized, controlled trials. Ann Intern
Med 130(10):800–809
8. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA,
Hamilton PA (1996) A comparison of low-dose heparin with low-
molecular-weight heparin as prophylaxis against venous thrombo-
embolism after major trauma. N Engl J Med 335(10):701–707
9. FrydmanA (1996) Low-molecular-weight heparins: an overview of
their pharmacodynamics, pharmacokinetics and metabolism in
humans. Haemostasis 26(Suppl 2):24–38
10. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS,
Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in
patients treated with low-molecular-weight heparin or
unfractionated heparin. N Engl J Med 332(20):1330–1335
11. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I,
Sa l loum A, Mura l idha ran V, Manthous CA (2004)
Anticoagulation in hospitalized patients with renal insufficiency: a
comparison of bleeding rates with unfractionated heparin vs
enoxaparin. Chest 125(3):856–863
Eur J Clin Pharmacol (2015) 71:921–929 927
12. Davis R, Faulds D (1997) Nadroparin calcium. A review of its
pharmacology and clinical use in the prevention and treatment of
thromboembolic disorders. Drugs Aging 10(4):299–322
13. Boneu B (2000) Low molecular weight heparins: are they superior
to unfractionated heparins to prevent and to treat deep vein throm-
bosis? Thromb Res 100(2):V113–V120
14. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW (2004)
Fixed dose subcutaneous low molecular weight heparins versus
adjusted dose unfractionated heparin for venous thromboembolism.
Cochrane Database Syst Rev 4, Cd001100. doi:10.1002/14651858.
CD001100.pub2
15. SamamaMM,Gerotziafas GT (2000) Comparative pharmacokinet-
ics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38
16. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y,
Bouthier J, Thebault JJ (1995) Comparison of the pharmacokinetic
profiles of three low molecular mass heparins–dalteparin,
enoxaparin and nadroparin–administered subcutaneously in healthy
volunteers (doses for prevention of thromboembolism). Thromb
Haemost 73(4):630–640
17. Boneu B, Caranobe C, Sie P (1990) Pharmacokinetics of heparin
and low molecular weight heparin. Baillieres Clin Haematol 3(3):
531–544
18. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight hep-
arin: the seventh ACCP conference on antithrombotic and throm-
bolytic therapy. Chest 126(3 SUPPL):188S–203S
19. Schmid P, Brodmann D, Fischer AG, Wuillemin WA (2010)
Prospective observational cohort study of bioaccumulation of
dalteparin at a prophylactic dose in patients with peritoneal dialysis.
J Thromb Haemost 8(4):850–852
20. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, D’Azemar P,
Necciari J, Duret JP, Gaud C, Decousus H, Boneu B (1998) Aging
and venous thromboembolism influence the pharmacodynamics of
the anti-factor Xa and anti-thrombin activities of a low molecular
weight heparin (nadroparin). Thromb Haemost 79(6):1162–1165
21. Becker RC, Spencer FA, GibsonM, Rush JE, SanderinkG,Murphy
SA, Ball SP, Antman EM, Investigators TA (2002) Influence of
patient characteristics and renal function on factor Xa inhibition
pharmacokinetics and pharmacodynamics after enoxaparin admin-
istration in non-ST-segment elevation acute coronary syndromes.
Am Heart J 143(5):753–759
22. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S,
Blais N, Lalonde L (2005) Dosage of enoxaparin among obese and
renal impairment patients. Thromb Res 116(1):41–50
23. Chow SL, Zammit K,West K, DannenhofferM, Lopez-Candales A
(2003) Correlation of antifactor Xa concentrations with renal func-
tion in patients on enoxaparin. J Clin Pharmacol 43(6):586–590
24. LimW, Dentali F, Eikelboom JW, Crowther MA (2006)Meta-anal-
ysis: low-molecular-weight heparin and bleeding in patients with
severe renal insufficiency. Ann Intern Med 144(9):673–684
25. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B,
Laurent M, Andruex JP, D’Urso M, Gaussem P (2000) Elderly
patients treated with tinzaparin (innohep(registered trademark)) ad-
ministered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa
activities over 10 days. Thromb Haemost 84(5):800–804
26. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V (2002) Safety
profile of tinzaparin administered once daily at a standard curative
dose in two hundred very elderly patients. Drug Saf 25(10):725–
733
27. Horlocker TT, Heit JA (1997) Low molecular weight heparin: bio-
chemistry, pharmacology, perioperative prophylaxis regimens, and
guidelines for regional anesthetic management. Anesth Analg
85(4):874–885
28. Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-
weight heparin in patients with renal insufficiency. Swiss Med
Wkly 139(31–32):438–452
29. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-
molecular-weight heparins in renal impairment and obesity: avail-
able evidence and clinical practice recommendations across medi-
cal and surgical settings. Ann Pharmacother 43(6):1064–1083
30. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009)
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Med 6(7), e1000097. doi:10.1371/
journal.pmed.1000097
31. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F,
Meade MO, Lee KA, Cook RJ (2005 ) Da l t epa r i n
thromboprophylaxis for critically ill medical-surgical patients with
renal insufficiency. J Crit Care 20(4):357–363. doi:10.1016/j.jcrc.
2005.09.009
32. Schmid P, Brodmann D, Fischer AG, Wuillemin WA (2009) Study
of bioaccumulation of dalteparin at a prophylactic dose in patients
with various degrees of impaired renal function. J ThrombHaemost
7(4):552–558
33. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y,
Albert M, Granton J, Hebert P, Pagliarello G, Marshall J, Fowler R,
Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D,
Crowther M (2008) Prophylaxis against deep vein thrombosis in
critically ill patients with severe renal insufficiency with the low-
molecular-weight heparin dalteparin: an assessment of safety and
pharmacodynamics: the DIRECT study. Arch Intern Med 168(16):
1805–1812
34. Tincani E,Mannucci C, Casolari B, Turrini F, CrowtherMA, Prisco
D, Cenci AM, Bondi M (2006) Safety of dalteparin for the prophy-
laxis of venous thromboembolism in elderly medical patients with
renal insufficiency: a pilot study. Haematologica 91(7):976–979
35. Mahe I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K,
Heilmann JJ, Mottier D, Bergmann JF (2007) Tinzaparin and
enoxaparin given at prophylactic dose for 8 days in medical elderly
patients with impaired renal function. A comparative pharmacoki-
netic study. Thromb Haemost 97(4):581–586
36. Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di Castillo H,
Siguret V, Bergmann JF, Pautas E (2007) Elderly medical patients
treated with prophylactic dosages of enoxaparin: influence of renal
function on anti-Xa activity level. Drugs Aging 24(1):63–71
37. Sanderink GJCM, Guimart CG, Ozoux ML, Jariwala NU, Shukla
UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacody-
namics of the prophylactic dose of enoxaparin once daily over
4 days in patients with renal impairment. Thromb Res 105(3):
225–231
38. Rico S, Antonijoan RM, Ballester MR, Gutierro I, Ayani I,
Martinez-Gonzalez J, Borrell M, Fontcuberta J, Gich I (2014)
Pharmacodynamics assessment of bemiparin after multiple prophy-
lactic and single therapeutic doses in adult and elderly healthy
volunteers and in subjects with varying degrees of renal impair-
ment. Thromb Res 133(6):1029–1038
39. Alban S, Peterfai E, Melzer N, Hagedorn I, De Mey C (2013)
Conventional prophylactic doses of certoparin do not cause exag-
gerated aXa-exposure in patients with severe renal insufficiency.
Hamostaseologie 33(1):A65
40. Polkinghorne KR, McMahon LP, Becker GJ (2002)
Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin
(Clexane), and danaparoid sodium (Orgaran) in stable chronic he-
modialysis patients. Am J Kidney Dis 40(5):990–995
41. Brown LS, Bourne RS, Kitchen S, VanVeen J, Byrne S (2010) A
service evaluation of venous thromboembolism prophylaxis with
low molecular weight heparin (LMWH) in intensive care patients
receiving continuous renal replacement therapy. Intensive Care
Med 36:S293
42. Isla A, Gascon AR, Maynar J, Arzuaga A, Corral E, Martin A,
Solinis MA, Munoz JL (2005) In vitro and in vivo evaluation of
enoxaparin removal by continuous renal replacement therapies with
928 Eur J Clin Pharmacol (2015) 71:921–929
acrylonitrile and polysulfone membranes. Clin Ther 27(9):1444–
1451. doi:10.1016/j.clinthera.2005.09.008
43. Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ,
Wong ST, Billett HH (2005) Peak antifactor xa activity produced by
dalteparin treatment in patients with renal impairment compared
with controls. Pharmacotherapy 25(6):817–822
44. Stobe J, Siegemund A, Achenbach H, Preiss C, Preiss R (2006)
Evaluation of the pharmacokinetics of dalteparin in patients with
renal insufficiency. Int J Clin Pharmacol Ther 44(10):455–465
45. Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM
(1991) Pharmacokinetics of a low molecular weight heparin
(Fraxiparine) in various stages of chronic renal failure. Nephron
59(4):543–545
46. Alhenc-Gelas M, Rossert J, Jacquot C, Aiach M (1995)
Pharmacokinetic study of the low-molecular-weight heparin
fraxiparin in patients with nephrotic syndrome. Nephron 71(2):
149–152
47. Martinez-Gonzalez J, Vila L, Rodriguez C (2008) Bemiparin: sec-
ond-generation, low-molecular-weight heparin for treatment and
prophylaxis of venous thromboembolism. Expert Rev Cardiovasc
Ther 6(6):793–802
48. Alban S, Peterfai E, Melzer N, Hagedorn I, De Mey C (2013)
Conventional therapeutic doses of certoparin do not lead to exag-
gerated aXa-levels in all the patients with severe renal insufficiency.
Hamostaseologie 33(1):A64
49. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight
SH, Sosolik RC (1998) College of American Pathologists
Conference XXXI on laboratory monitoring of anticoagulant ther-
apy: the clinical use and laboratory monitoring of low-molecular-
weight heparin, danaparoid, hirudin and related compounds, and
argatroban. Arch Pathol Lab Med 122(9):799–807
50. Davies RG, Rayment R (2010) Primum non nocere—NICE guide-
lines on venous thromboembolism. Anaesthesia 65(8):774–778
51. Lim W, Cook DJ, Crowther MA (2004) Safety and efficacy of low
molecular weight heparins for hem dialysis in patients with end-
stage renal failure: a meta-analysis of randomized trials. J Am Soc
Nephrol 15(12):3192–3206
52. Rodger MA, Ramsay T, MacKinnon M, Westphal M, Wells PS,
McCormick B, Knoll G (2012) Tinzaparin versus dalteparin for
periprocedure prophylaxis of thromboembolic events in hemodial-
ysis patients: a randomized trial. Am J Kidney Dis 60(3):427–434
53. Hene IZ, Wiertz NR, Van Schilfgaarde M, Wester JPJ, Leyte A,
Oudemans-Van Straaten HM (2009) Nadroparin anticoagulation
in continuous venovenous hemofiltration (CVVH): kinetics and
extracorporeal removal. Intensive Care Med 35:S44
54. Nurmohamed MT, ten Cate J, Stevens P, Hoek JA, Lins RL, ten
Cate JW (1991) Long-term efficacy and safety of a low molecular
weight heparin in chronic hemodialysis patients. A comparison
with standard heparin. ASAIO Trans 37(3):M459–461
55. Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler
MJ, Cox DS,Williams RM, Pittenger AL, Stephenson CA, Hua TA
(2002) Intravenous and subcutaneous weight-based dosing of the
low molecular weight heparin tinzaparin (Innohep) in end-stage
renal disease patients undergoing chronic hemodialysis. Am J
Kidney Dis 40(3):531–538
56. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M
(1989) The relationship between anti-factor Xa level and clinical
outcome in patients receiving enoxaparine low molecular weight
heparin to prevent deep vein thrombosis after hip replacement.
Thromb Haemost 62(3):940–944
57. Leizorovicz A, Bara L, SamamaMM, HaughMC (1993) Factor Xa
inhibition: correlation between the plasma levels of anti-Xa activity
and occurrence of thrombosis and haemorrhage. Haemostasis
23(Suppl 1):89–98
58. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME (2004)
Antifactor Xa activity correlates to thrombin generation time, plate-
let contractile force and clot elastic modulus following ex vivo
enoxaparin exposure in patients with andwithout renal dysfunction.
J Thromb Haemost 2(8):1299–1304
59. Brophy DF, Martin EJ, Gehr TW, Carr ME Jr (2004) Enhanced
anticoagulant activity of enoxaparin in patients with ESRD as mea-
sured by thrombin generation time. Am J Kidney Dis 44(2):270–
277
60. Al Dieri R, Alban S, Beguin S, Hemker HC (2006) Fixed dosage of
low-molecular-weight heparins causes large individual variation in
coagulability, only partly correlated to body weight. J Thromb
Haemost 4(1):83–89
61. Lim W (2010) Using low molecular weight heparin in special pa-
tient populations. J Thromb Thrombolysis 29(2):233–240
62. Boneu B, de Moerloose P (2001) How and when to monitor a
patient treated with low molecular weight heparin. Semin Thromb
Hemost 27(5):519–522
63. Smith BS, Gandhi PJ (2001) Pharmacokinetics and pharmacody-
namics of low-molecular-weight heparins and glycoprotein IIb/IIIa
receptor antagonists in renal failure. J Thromb Thrombolysis 11(1):
39–48
Eur J Clin Pharmacol (2015) 71:921–929 929
